WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Spinoff

J&J targets mid-2027 to separate DePuy Synthes as MedTech sales miss

MedDevice Startups Staff · Oct 13 · 2 min read · Via MassDevice

Johnson & Johnson plans to separate DePuy Synthes by mid-2027 and now calls a spin-off more likely than a sale. Earlier reports had put the company in talks with Apollo Global Management over the orthopedics unit.

MedTech sales came in at $8.64B for the third quarter, up 2.5 percent and below the $8.74B consensus. Orthopedics grew 3.4 percent to $2.34B. Surgery fell 1.0 percent to about $2.53B as international sales dropped 4.2 percent. Cardiovascular rose 4.1 percent to $2.31B, with Abiomed Impella down 1.5 percent and Shockwave international sales up 17.2 percent. The stock fell more than 5 percent on the day.

An independent DePuy Synthes becomes a buyer with its own balance sheet and its own appetite, which changes the exit math for ortho and spine companies now raising. J&J has set December 8 for an enterprise business review that includes a 2027 outlook for its Ottava surgical robot.

Questions & Answers

When will Johnson & Johnson separate DePuy Synthes?

Johnson & Johnson said on October 13, 2026 that it targets mid-2027 to separate its DePuy Synthes orthopedics unit. Executives said a spin-off is now more likely than a sale.

How did Johnson & Johnson MedTech perform in the third quarter of 2026?

J&J MedTech reported $8.64 billion in third-quarter 2026 sales, up 2.5 percent year over year and below the $8.74 billion consensus estimate.

Which J&J MedTech segments were weakest in the third quarter of 2026?

Surgery fell 1.0 percent to about $2.53 billion, dragged down by a 4.2 percent drop in international sales. The CFO named Cardiovascular and Surgery outside the United States as the areas needing improvement.

← Back to M&A